Literature DB >> 7618540

Selective use of image-guided large-core needle biopsy of the breast: accuracy and cost-effectiveness.

A J Doyle1, K A Murray, E W Nelson, D G Bragg.   

Abstract

OBJECTIVE: We examined the accuracy and cost-effectiveness of large-core needle breast biopsy in a selected group of patients with mammographically detected lesions.
MATERIALS AND METHODS: We selectively used large-core needle biopsy to sample breast lesions that were intermediate (neither clearly benign nor clearly malignant) and wire localization biopsy to sample breast lesions that were strongly suggestive of cancer. We compared 2 years' experience using this protocol with the preceding 2 years at the University of Utah Health Sciences Center during which we did only a few large-core needle biopsies on a nonselective basis.
RESULTS: Our biopsy rate increased from one biopsy per 36 mammographic screening examinations to one per 26 (p = .001) when the protocol was used. The cost of biopsy per cancer detected decreased from $11,555 to $8356. The specificity of large-core needle biopsy was 98%; the sensitivity based on limited follow-up was 100%.
CONCLUSION: Large-core needle biopsy is an accurate and cost-effective method for sampling breast lesions when used in a selective fashion.

Entities:  

Mesh:

Year:  1995        PMID: 7618540     DOI: 10.2214/ajr.165.2.7618540

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

1.  The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions.

Authors:  A E Ibrahim; A C Bateman; J M Theaker; J L Low; B Addis; P Tidbury; C Rubin; M Briley; G T Royle
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

2.  Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening.

Authors:  Costas G Hadjipanayis; Huabei Jiang; David W Roberts; Lily Yang
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 3.  In situ breast cancer.

Authors:  R S Henry-Tillman; V S Klimberg
Journal:  Curr Treat Options Oncol       Date:  2000-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.